| 奥希替尼获得性耐药的研究进展 |
| |
| 引用本文： | 裴清华,孙建立. 奥希替尼获得性耐药的研究进展[J]. 中国临床药理学与治疗学, 2021, 0(1) |
| |
| 作者姓名： | 裴清华 孙建立 |
| |
| 作者单位： | 上海中医药大学附属龙华医院肿瘤六科 |
| |
| 基金项目： | 国家自然科学基金面上项目(81573890);国家中医药管理局中医临床研究基地业务建设科研专题课题(JDZX2015069);刘嘉湘国医大师传承工作室建设项目(DSGZS-2017002);龙华医院中青年名中医培养项目(CX202017)。 |
| |
| 摘 要： | 奥希替尼作为第三代表皮生长因子受体酪氨酸激酶抑制剂,对表皮生长因子受体(EGFR)T790M突变型肺腺癌有显著疗效。随着临床研究的深入,奥希替尼的耐药逐渐出现。如何应对奥希替尼耐药已成为临床工作者必须关注的问题。本文就奥希替尼获得性耐药机制及应对措施的最新研究进展进行综述。
|
| 关 键 词： | 奥希替尼 非小细胞肺癌 耐药 研究进展 |
Research progress of Osimertinib acquired resistance |
| |
| PEI Qinghua,SUN Jianli. Research progress of Osimertinib acquired resistance[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 0(1) |
| |
| Authors: | PEI Qinghua SUN Jianli |
| |
| Affiliation: | (No.6 Department of Oncology,Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200030,China) |
| |
| Abstract: | Osimertinib,as a representative of the third generation epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI),has significant curative effect for EGFR T790M mutation type non-small cell lung cancer(NSCLC).But with the development of clinical research Osimertinib's resistance gradually appear.How to deal with the resistance is a problem that the clinical workers must focus on.This article will review the latest research progress of the mechanisms and the solutions of osimertinib acquired resistance. |
| |
| Keywords: | Osimertinib non-small cell lung cancer acquired resistance research progress |
| 本文献已被 维普 等数据库收录！ |
